Pre-participation cardiovascular screening using history taking and physical examination alone (without noninvasive testing) is not sufficient to guarantee the absence of many critical cardiovascular abnormalities in older trained athletes. Indeed, hemodynamically significant congenital aortic valve stenosis is probably the most likely lesion to be reliably detected during routine screening because of its characteristically loud heart murmur. Detection of hypertrophic cardiomyopathy by standard screening is unreliable, because most patients have the nonobstructive form of this disease, characteristically expressed by only a soft heart murmur or none
[14, 15, 16, 17]. Furthermore, most athletes with hypertrophic cardiomyopathy do not experience syncope or have a family history of premature sudden death due to the disease
[3, 18].
The standard history taking and physical examination generally conveys low specificity for the detection of many cardiovascular abnormalities. In older athletes, however, a personal history of coronary risk factors can be useful for identifying the individuals at risk.
The 12-lead ECG has been proposed as a more practical and cost-effective alternative to routine echocardiography for population-based screening
[19, 20]. Indeed, the ECG is abnormal in about 95% of the patients with hypertrophic cardiomyopathy
[21], and is frequently abnormal in other potentially lethal lesions such as coronary anomalies
[12], and will usually identify the important but uncommon long QT syndrome
[22, 23]. Recent data indicate that a certain proportion of genetically affected relatives in families with long QT syndrome may have little or no phenotypic expression on ECG
[22]. However, these problems are not common in older athletes. In pre-participation screening, ECG is compared unfavorably with the echocardiogram because of its lack of imaging capability for recognition of structural cardiovascular malformations. ECG also has a relatively low specificity as a screening test in athletic populations because of the high frequency of electrocardiographic alterations that are associated with normal physiological adaptations of an athlete's heart to training
[24]. On the other hand, normal ECG cannot rule out coronary artery disease in older athletes.
In screening large populations of older trained athletes, the routine use of exercise testing to detect coronary artery disease is limited by its low specificity and pretest probability
[25]. American College of Sports Medicine (ACSM) has recommended routine use of exercise testing for all male athletes over 40, female athletes over 50 and athletes with coronary risk factors. In athletes over 30 years old, coronary artery disease is an important problem, but real possibility of myocardial infarction (MI) and sudden cardiac death during exercise is low; therefore, the routine use of exercise testing is not recommended except when there is a cardiac symptom such as chest discomfort or when there are coronary risk factors
[26]. In a study on 102 unprofessional football players with an average age of 45.5 years old, exercise test was positive in 52%
[27].
Echocardiography can also be expected to detect other relevant abnormalities associated with sudden death, such as valvular heart disease, aortic root dilatation, and left ventricular dysfunction (with myocarditis and dilated cardiomyopathy) in addition to regional wall motion abnormality due to coronary artery disease in older athletes. However, even such diagnostic testing cannot by itself guarantee the identification of all important lesions, and some diseases that may not be detectable with any screening method
[28].
The potential false-positive or false-negative results is another important limitation of screening with two-dimensional echocardiography. False-positive results may arise from the assignment of borderline values for left ventricular wall thicknesses (or particularly large values for cavity size) that require formulation of a differential diagnosis between the normal physiological adaptations of an athlete's heart
[29, 30, 31] and pathological conditions such as hypertrophic cardiomyopathy or other cardiomyopathies
[33]. In fact, such clinical dilemmas (which cannot be definitively resolved in some athletes) generate heavy emotional, financial, and medical burdens for the athletes, their families and the team for performing additional testing.
Cost-efficiency issues are important in assessing the feasibility of screening large athletic populations
[33]. There have been relatively few published reports of cardiovascular screening efforts in large older athletic populations so far. Most of the studies on athletes have implemented noninvasive testing (i.e., conventional or limited echocardiogram or 12-lead ECG) in high school or collegiate athletes. We hope that our study helps to clarify the role of noninvasive testing (12-lead ECG, echocardiography and exercise testing) in elderly athletes.